|Year : 2012 | Volume
| Issue : 1 | Page : 50-52
Relevance of an incidental chest finding
Arturo Cortés-Télles1, Daniel Mendoza2
1 Department of Clinical Pneumology, National Institute of Respiratory Diseases Dr. Ismael Cosio Villegas, Mexico City, Mexico
2 Department of Oncology, National Institute of Respiratory Diseases Dr. Ismael Cosio Villegas, Mexico City, Mexico
|Date of Web Publication||28-Jan-2012|
National Institute of Respiratory Diseases "Dr. Ismael Cosio Villegas", Calzada de Tlalpan, #4502, Col Sección XVI, C.P. 14080 Tlalpan
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Solitary pulmonary nodule represents 0.2% of incidental findings in routine chest X-ray images. One of the main diagnoses includes lung cancer in which small-cell subtype has a poor survival rate. Recently, a new classification has been proposed including the very limited disease stage (VLD stage) or T1-T2N0M0 with better survival rate, specifically in those patients who are treated with surgery. However, current recommendations postulate that surgery remains controversial as a first-line treatment in this stage. We present the case of a 46-year-old female referred to our hospital with a preoperative diagnosis of a solitary pulmonary nodule. On initial approach, a biopsy revealed a small cell lung cancer. She received multimodal therapy with surgery, chemotherapy, and prophylactic cranial irradiation and is currently alive without recurrence on a 2-year follow-up.
Keywords: PET scan, prophylactic cranial radiotherapy, small cell lung cancer, surgical treatment, very limited disease
|How to cite this article:|
Cortés-Télles A, Mendoza D. Relevance of an incidental chest finding. Lung India 2012;29:50-2
| Introduction|| |
A solitary pulmonary nodule (SPN) is defined as a well-circumscribed round or oval lung opacity of less than 3 cm in diameter, which is completely surrounded by parenchyma and unassociated with atelectasis, lymph node enlargement, pneumonia, or pleural effusion.  Differential diagnoses include lung cancer among others.  Most of SPNs are incidentally detected (0.2% of chest X-ray). When the diameter is greater than 20 mm, the risk of malignancy can be as high as 82% (Odds Ratio 3.67).  Worldwide lung cancer is the first cause of cancer-related mortality. Besides small cell lung cancer (SCLC) represents 13-25% of deaths by lung cancer, is highly sensitive to chemotherapy (CHT) and radiotherapy (RT).  On the other hand, surgery as a therapeutic strategy in SCLC is still matter of controversy. 
We report the case of a woman in her fifth decade of life referred to our hospital with an incidental SPN finding. A biopsy revealed the presence of SCLC and received a multimodal therapeutic strategy including surgery, adjuvant CHT, and prophylactic cranial irradiation (PCI) with no recurrence over a period of two years of follow-up.
| Case Report|| |
A 46-year-old female, referred to our hospital with a SPN in the right upper lobe (RUL) lung, which was incidentally identified during a preoperatory evaluation (umbilical hernia repair). She is a current smoker (4 pack-years) and has a clinical history of hypertension under treatment.
On initial examination her vital signs were normal. An abdominal exam revealed a 2 cm umbilical hernia. A positron emission tomography (PET) of the chest confirmed a hypodense zone in the posterior segment of the RUL positive to [ 18 F] fluoro-2-deoxy-D-glucose (FDG) with 2.5 standard uptake value (SUV) [Figure 1]a.
|Figure 1: (a) PET/CT scan shows a SPN with intense enhancement to FDG in the posterior segment of the right upper lobe; (b) Intrabronchial neoplastic cells disposed as nests-like distribution. Hematoxylin and eosin stain (H and E, 10×)|
Click here to view
A nonanatomical resection of the nodule was performed. The pathological diagnosis was SCLC [Figure 1]b and [Figure 2]a. Staging work-up included a magnetic resonance imaging (MRI) of the brain, abdominal computed tomography (CT), and a radionuclide bone scan (RBS) with no evidence of metastases. Thereafter, the staging was classified as a VLD stage SCLC or T1N0M0. The local surgical consensus decided to make a right-upper lobectomy with lymph-nodes dissection.
|Figure 2: (a) Neoplastic cells with scant cytoplasm, fine chromatin, and round nucleus (H and E, 40×); (b) PET/CT chest scan during follow-up without evidence of recurrence.|
Click here to view
Both RUL and lymph nodes showed no residual neoplastic activity. The initial performance status was Karnofsky 70% and ECOG - 1. Adjuvant CHT began with cisplatin/etoposide and after six cycles the performance status improved (Karnofsky 100% and ECOG - 0). Thereafter, was submitted to PCI with a conventional fractionated dose of 20 Gy. A subsequent evaluation with brain MRI showed no evidence of metastases.
During a follow-up period of two years, two PET/CT scans were performed without recurrence [Figure 2]b. Currently, the patient had a complete response (CR) to treatment.
| Discussion|| |
Most of the SPN are incidentally detected (0.2% of chest X-rays images). Approximately, 70% of lung cancer manifesting as SPN is located in the lung's RUL.  Several morphologic features on CT scans are useful in assessing a nodule's malignant potential including spiculated margins, lobular or irregular contour, heterogeneous attenuation (after contrast injection enhance more than 20 Hounsfield units), the halo sign, and the growth rate among others. According to the American Cancer Society, overall lifetime odds to develop lung cancer are almost 1 in 13 and 1 in 16 for men and woman, respectively, of these between 20% and 30% will present as an SPN. 
Recently, it has been suggested to include the VLD stage in the classification of SCLC, which is defined as no preoperative evidence of regional lymph nodes involved. ,, This reassignment has wide implications on therapeutic strategies because initial randomized data are in favor of using RT over surgery combined with CHT as first-line treatment. However, recent studies have shown a reasonable survival rate in patients who underwent surgery plus CHT as curative-intent therapy for VLD-stage SCLC. , Most recently, Yu et al. analyzed 247 patients who underwent surgical lobectomy with or without thoracic RT (TRT) for stage I SCLC. Surgery per se offers a 3- and 5-year survival rate of 58% and 50%, respectively, without TRT.  Notwithstanding, current evidence-based clinical guidelines have no conclusion on surgery as first-line treatment in cases of VLD-stage SCLC.  However, surgeons will undoubtedly continue to offer surgery to T1-T2N0 patients although remains controversial. 
Brain metastases (BM) will emerge over the next 2 years in approximately 50%-60% of patients who achieved a CR. A meta-analysis found that the PCI increased 5.4% survival rate at 3 years and reduced the incidence of BM from 59% to 33%. Also a positive effect was found with highest radiation doses (30-36 Gy) applied during 6 weeks after last CHT. ,
During the follow-up, it is recommended to investigate recurrence and metastasis. A useful test is PET/CT which can be used to evaluate recurrence and residual disease during the initial and follow-up investigations. Identification of residual disease that can only be detected by functional imaging could be important in lending salvage therapy opportunity to a specific subset of patients.  Any change in the FDG capitation provides information on the evolution of the disease as well as failure or success in treatment. ,
Since the clinical stage of SCLC has a remarkable relevance regarding prognosis and therapeutics implications, an opportune diagnosis is associated with a better survival. Multimodal treatment including surgical management and CHT showed a survival rate in VLD-stage SCLC as high as 50%. 
In spite of the controversy related to surgery as initial therapeutic strategy in VLD stage of SCLC, our case represents a successful example of an opportune surgical procedure which has had repercussions in the survival rate of the patient. In a multimodal therapy PCI seem to have an adjuvant role. Functional imaging such as PET may be helpful is this clinical situation, but the scientific validity needs to be prospectively evaluated.
| References|| |
|1.||Klein JS, Braff S. Imaging evaluation of the solitary pulmonary nodule. Clin Chest Med 2008;29:15-38. |
|2.||Wahidi MM, Govert JA, Goudar RK, Gould MK, McCrory DC. American College of Chest Physicians. Evidence for the treatment of patients with pulmonary nodules: When is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:94S-107S. |
|3.||Gould MK, Fletcher J, Iannettoni MD, Lynch WR, Midthun DE, Naidich DP, et al. Evaluation of patients with pulmonary nodules: When is it lung cancer?: ACCP evidence-based clinical practice guidelines (2 nd edition). Chest 2007;132:108S-30S. |
|4.||Vallieres E, Shepherd FA, Crowley J, van Houtte P, Postmus PE, Carney D, et al. The IASLC Lung Cancer Staging Project: Proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009;4:1049-59. |
|5.||Samson DJ, Seidenfeld J, Simon GR, Turrisi AT 3 rd , Bonnell C, Ziegler KM, et al. American College of Chest Physicians. Evidence for management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2 nd edition). Chest 2007;132:314S-23S. |
|6.||Truong MT, Sabloff BS, Ko JP. Multidetector CT of solitary pulmonary nodules. Radiol Clin North Am 2010;48:141-55. |
|7.||Lim E, Belcher E, Yap YK, Nicholson AG, Goldstraw P. The role of surgery in the treatment of limited disease small cell lung cancer: time to reevaluate. J Thorac Oncol 2008;3:1267-71. |
|8.||de Antonio DG, Alfageme F, Varela A. Bronchogenic carcinoma cooperative group of the spanish society of pneumology and thoracic surgery (GCCB-S). Results of surgery in small cell carcinoma of the lung. Lung Cancer 2006;52:299-04. |
|9.||Koletsis EN, Prokakis C, Karanikolas M, Apostolakis E, Dougenis D. Current role of surgery in small cell lung carcinoma. J Cardiothorac Surg 2009;4:30. |
|10.||Yu JB, Decker RH, Detterbeck FC, Wilson LD. Surveillance epidemiology and end results evaluation of the role of surgery for stage I small cell lung cancer. J Thorac Oncol 2010;5:215-9. |
|11.||Sorensen M. Primary surgery revisited in very limited small cell lung cancer: Does it have a role? A commentary. Lung Cancer 2006;52:263-4. |
|12.||Simon GR, Turrisi A. American College of Chest Physicians. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132:324S-39S. |
|13.||Arriagada R, Pignon JP, Gregor A, Stephens RJ, Kristjansen PE, Johnson BE, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999;341:476-84. |
|14.||Onitilo AA, Engel JM, Demos JM, Mukesh B. Prognostic significance of 18 F-fluorodeoxyglucose - positron emission tomography after treatment in patients with limited stage small cell lung cancer. Clin Med Res 2008;6:72-7. |
|15.||Chen J, Jiang R, Garces YI, Jatoi A, Stoddard SM, Sun Z, et al. Prognostic factors for limited-stage small cell lung cancer: A study of 284 patients. Lung Cancer 2010;67:221-6. |
[Figure 1], [Figure 2]